FDA Approves ARIKAYCE — Insmed Incorporated

Brookline, Massachusetts-based Insmed Incorporated announced Wednesday that JAMA reports suggest the amikacin inhaled formulation ARIKAYCE could improve survival for cystic fibrosis patients with chronic Pseudomonas infections, signaling a potential shift in the ability to treat severe pulmonary infections and awaiting a final FDA decision. If approved, Nasdaq-listed Insmed would join a narrow pool of inhaled drug manufacturers, a move that is likely to drive significant investor interest and anticipation regarding the near-term commercial outlook for its respiratory portfolio.